ニュース
Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.
16 時間
Zacks Investment Research on MSNAstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...
Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...
US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...
Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
A bold move by US President Donald Trump to slash the cost of prescription drugs in America has sent shockwaves through the ...
US President Donald Trump has signed an executive order that aims to reduce high prescription drug prices – but its details ...
Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...
Announcement pressures pharma stocks on worries profits will be hit if they have to cut prices in US. Read more at ...
Business leaders from major Hoosier companies say they are trying to navigate the uncertain trade environment created by ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する